Single Chain Antibodies Targeting 3R Tau for Neurodegenerative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for neurodegenerative disorders like Alzheimer's Disease and Pick's Disease primarily target total Tau or phosphorylated Tau, which may have deleterious effects and are not specifically designed to target 3-repeat (3R) Tau, a key protein associated with these conditions, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of single chain antibodies (scAbs) that specifically target 3R Tau, engineered to cross the blood-brain barrier, using a fragment of the apoB protein for enhanced brain penetration, reducing 3R Tau accumulation and associated symptoms without affecting total Tau levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current immunotherapy approaches target total Tau or phosphorylated Tau, then therapeutic coverage is broad, but specificity for 3R Tau is insufficient leading to inadequate therapeutic outcomes
Solution Approach 1:
The patent segments the Tau protein target by developing antibodies that specifically recognize and bind to the 3-repeat (3R) Tau isoform rather than targeting total Tau or phosphorylated Tau. This segmentation allows selective targeting of the pathogenic 3R Tau species while sparing other Tau isoforms, thereby improving both specificity and therapeutic efficacy in treating taupathies like Pick's disease
Solution Approach 2:
The patent applies local quality by engineering antibodies with specific epitope recognition capabilities tailored to distinguish 3R Tau from 4R Tau and other Tau variants. The antibodies are designed to recognize specific conformational or linear epitopes unique to 3R Tau, enabling localized and selective immunotherapy action against the pathogenic isoform
2Area of stationary object
If antibodies are engineered to cross the blood-brain barrier using apoB protein fragments, then brain penetration is enhanced, but molecular complexity increases
Solution Approach 1:
The patent merges two functional components into a single molecular construct: the antigen-binding fragment (scFv) that specifically recognizes 3R Tau and the apoB protein fragment that facilitates blood-brain barrier penetration. This merged construct (scFv-apoB fusion protein) combines targeting specificity with enhanced brain delivery capability in one molecule, improving therapeutic efficacy while streamlining the delivery system
Solution Approach 2:
The apoB protein fragment acts as an intermediary that mediates blood-brain barrier crossing. By fusing apoB to the scFv antibody fragment, the construct utilizes apoB's known ability to interact with LDL receptors on brain endothelial cells to facilitate transcytosis, thereby enabling the therapeutic antibody to reach its target in the brain without requiring complex delivery systems
3Speed
If single chain antibodies are used instead of full antibodies, then brain penetration improves, but binding affinity may be reduced
Solution Approach 1:
The patent optimizes the scFv sequence through affinity maturation and engineering to enhance binding affinity despite the reduced size compared to full antibodies. By modifying amino acid sequences in the complementarity-determining regions (CDRs) and framework regions, the scFv achieves high-affinity binding to 3R Tau while maintaining the size and penetration advantages of single-chain fragments
Solution Approach 2:
The patent creates a composite molecular structure by fusing the scFv antibody fragment with the apoB protein fragment. This composite construct combines the high-specificity antigen-binding capability of the scFv with the brain-penetrating properties of apoB, achieving both rapid brain entry and strong target binding in a single therapeutic molecule
Data Source
AI summary
In alternative embodiments, provided are compositions such as antibodies, e.g., single chain antibodies, that target 3-repeat (3R) Tau for the treatment of neurodegenerative disorders and taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation, and methods for making and using them. In alternative embodiments, provided are brain-penetrating antibodies that specifically recognize 3R Tau, and methods of using them to treat, ameliorate, prevent or decrease the symptoms of neurodegenerative disorders including taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation. Provided are methods for diagnosing a neurodegenerative disorder or a taupathy or any disorder or condition associated with a 3R Tau accumulation, and optionally the taupathy is Alzheimer's Disease, Pick's Disease or Fronto-temporal lobar degeneration.